
	Three Months Ended June 30,				Six Months Ended June 30,
(In Thousands, Except Per Share Amounts)	2026		2025		2026		2025
Basic Earnings/(Loss) per Share:
Net income/(loss) to common stockholders	$	46,798	$	33,184	$	45,814	$	74,360
Dividends declared on preferred stock	(10,559)		(10,560)		(20,983)		(18,779)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities	(309)		(200)		(627)		(406)
Net income/(loss) attributable to common stockholders - basic	$	35,930	$	22,424	$	24,204	$	55,175
Basic weighted average common shares outstanding	103,674		103,705		103,962		103,740
Basic Earnings/(Loss) per Share	$	0.35	$	0.22	$	0.23	$	0.53

Diluted Earnings/(Loss) per Share:
Net income/(loss) to common stockholders - basic	$	35,930	$	22,424	$	24,204	$	55,175
Dividends, dividend equivalents and undistributed earnings allocated to participating securities	—		—		—		—

Net income/(loss) attributable to common stockholders - diluted	$	35,930	$	22,424	$	24,204	$	55,175
Basic weighted average common shares outstanding	103,674		103,705		103,962		103,740
Unvested and vested restricted stock units	1,764		1,602		1,691		1,536

Diluted weighted average common shares outstanding (1)	105,438		105,307		105,653		105,276
Diluted Earnings/(Loss) per Share	$	0.34	$	0.21	$	0.23	$	0.52

(1)At June 30, 2026 and 2025, the Company had approximately 1,021,000 and 931,000 equity instruments outstanding that were excluded from the calculation of diluted EPS for the three and six months ended June 30, 2026 and 2025, as they were determined to be anti-dilutive. These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $9.94 and $10.45, respectively. These equity instruments may have a dilutive impact on future EPS.